Man Survives Shipwreck Clinging to Refrigerator Door in São Francisco do Sul
- The Inflation Reduction Act (IRA), signed into law on August 16, 2022, allows Medicare to negotiate prices for certain high-expenditure prescription drugs, aiming to lower healthcare costs for...
- government refrained from direct price negotiation, relying instead on market competition and other mechanisms.
- As of November 2023, the Centers for Medicare & Medicaid Services (CMS) announced the first 10 drugs selected for Medicare price negotiation, effective in 2026.
“`html
The Inflation Reduction Act and prescription Drug Pricing
Table of Contents
The Inflation Reduction Act (IRA), signed into law on August 16, 2022, allows Medicare to negotiate prices for certain high-expenditure prescription drugs, aiming to lower healthcare costs for seniors and taxpayers. This marks a notable shift in U.S. policy, as previously Medicare was prohibited from directly negotiating drug prices with manufacturers.
For decades, the U.S. government refrained from direct price negotiation, relying instead on market competition and other mechanisms. The IRA addresses concerns that pharmaceutical companies were charging excessive prices, especially for drugs without competition. The law’s provisions are being implemented in phases,starting with a limited number of drugs and expanding over time. The Congressional Budget Office (CBO) initially estimated the IRA would reduce federal deficits by $265.2 billion over ten years, with $98.5 billion attributed to prescription drug savings. However, updated CBO estimates in February 2024 revised the projected savings downward to $162.7 billion over the same period.
As of November 2023, the Centers for Medicare & Medicaid Services (CMS) announced the first 10 drugs selected for Medicare price negotiation, effective in 2026. CMS Press Release. These drugs treat conditions like diabetes, heart failure, and blood clots. The negotiated prices are expected to be available to Medicare beneficiaries starting in 2026.
How Medicare Drug Price Negotiation Works
Medicare’s drug price negotiation process, established by the IRA, involves several key steps. The Secretary of health and Human Services (HHS) identifies eligible drugs – those without generic or biosimilar competition and with high Medicare spending.Drug manufacturers then submit offers to CMS, and negotiations occur over a defined period.
The law prioritizes drugs that have been on the market for a certain length of time, excluding new medications. this phased approach aims to balance cost savings with incentives for pharmaceutical innovation. Negotiations focus on single-source brand-name drugs, meaning those without generic alternatives.CMS publishes the negotiated prices, and these prices are then available to Medicare beneficiaries thru their prescription drug plans. manufacturers who refuse to participate in negotiations face significant excise taxes.
The initial 10 drugs selected for negotiation represent $50.5 billion in Medicare spending in 2022, according to CMS. CMS Fact Sheet. These drugs include Eliquis (apixaban), Jardiance (empagliflozin), Xarelto (rivaroxaban), Januvia (sitagliptin), Farxiga (dapagliflozin), Entresto (sacubitril/valsartan), Imbruvica (ibrutinib), Stelara (ustekinumab), Fiasp/novolog (insulin aspart), and Byetta (exenatide).
Challenges and Legal Battles
The implementation of the IRA’s drug price negotiation provisions has faced significant legal challenges from the pharmaceutical industry. Several lawsuits were filed arguing that the law violates the Fifth Amendment’s Takings Clause and Due Process Clause, as well as federal administrative law.
Pharmaceutical Research and Manufacturers of America (PhRMA),the industry’s main lobbying group,has been a leading opponent of the IRA. They argue that the law will stifle innovation and reduce investment in the development of new drugs. The lawsuits claim that the negotiation process is coercive and that the mandated price reductions amount to a taking of private property without just compensation. However, in December 2023, a federal judge dismissed a lawsuit brought by PhRMA challenging the constitutionality of the IRA. Reuters Report.
On January 9, 2024, the Eighth Circuit court of Appeals heard oral arguments in a separate case brought by the national Association of Community Pharmacists challenging the IRA’s drug price negotiation provisions. Fierce Pharma Report. The outcome of this case, and potential appeals to the Supreme Court, could further shape the future of drug pricing in the U.S.
Impact on Pharmaceutical innovation
A central concern surrounding the IRA is its potential impact on pharmaceutical innovation. Opponents argue that reduced revenues from negotiated drug prices will lead to decreased investment in research and development (R&D),ultimately slowing the development of new treatments.
The Congressional Budget Office (CBO) has analyzed this issue, estimating that the IRA could lead to a reduction in the number of new drugs developed over the next decade. Though, the extent of this reduction is uncertain and depends on how pharmaceutical companies respond to the new pricing environment. Some argue that companies may shift their R&D focus towards areas with less price pressure, such as rare diseases or innovative therapies. Others suggest that the IRA could incentivize